Lacosamide Injection
Product Images NDC 72266-242

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 72266-242). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fosun Pharma Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lacosamide-structure (Lacosamide Structure)

Chemical structure of lacosamide. The diagram shows the molecular arrangement including acetyl and phenyl groups, characteristic of the lacosamide molecule used in the injection dosage form by Fosun Pharma USA.*

FDA Label Image

Lacosamide Carton Label (Lacosamide Carton Label)

Lacosamide Injection, USP 200 mg/20 mL (10 mg/mL) intravenous injection carton labeled for Fosun Pharma. The package contains 5 single-dose vials of 20 mL solution for infusion each. The label includes storage instructions, inactive ingredients, and distribution information, indicating it is made in India and distributed by Fosun Pharma USA.*

FDA Label Image

Lacosamide Vial Label (Lacosamide Container Label)

Lacosamide Injection, USP 10 mg/mL (200 mg/20 mL) single-dose vial for intravenous use. The label includes the NDC 72266-242-01 and states it is distributed by Fosun Pharma USA Inc., Princeton, NJ. The vial volume is 20 mL, with instructions for intravenous use only and storage directions to keep out of reach of children.*

FDA Label Image

Lacosamide-figure-1 (Lacosamide Figure 1)

A bar graph titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' comparing placebo and lacosamide at various dosages across three studies. The graph shows median percent reduction in seizure frequency with lacosamide doses of 200, 400, and 600 mg/day generally demonstrating higher reductions compared to placebo, with some differences marked as statistically significant.*

FDA Label Image

Lacosamide-figure-2 (Lacosamide Figure 2)

A line graph showing the proportion of patients by responder rate comparing Lacosamide and placebo groups in clinical Studies 2, 3, and 4. The x-axis represents the percent of patients from 0 to 100, and the y-axis shows responder rate from -100% (worsening) to 100% (improvement). Four lines depict placebo and Lacosamide at doses of 200 mg/day, 400 mg/day, and 600 mg/day, illustrating variation in responder rates across these groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.